Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2023

High-Dose Aflibercept: 48-Week Data

Show Description +

Diana V. Do, MD, FASRS, reviews the latest findings from the phase 2/3 PHOTON trial of 8 mg aflibercept for diabetic macular edema.

Posted: 8/08/2023

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS, reviews the latest findings from the phase 2/3 PHOTON trial of 8 mg aflibercept for diabetic macular edema.

Posted: 8/08/2023


Please log in to leave a comment.

More From ASRS: 2023 Coverage